Status epilepticus management in patients with brain tumors. A cohort study.

Seizure

Department of Clinical Neurosciences, Neurology service, CHUV and University of Lausanne, Lausanne, Switzerland. Electronic address:

Published: August 2024

Purpose: Status epilepticus (SE) represents a neurological emergency with significant morbidity and mortality. SE in patients with primary brain tumors received only limited attention to date; detailed analysis of treatment flow is lacking, especially as compared to other SE causes. This study aims to describe the frequency and treatment flow of tumor-related SE and compare it to other SE etiologies.

Methods: Retrospective cohort study based on an institutional SE registry (SERCH) comprising adult SE (excluding post-anoxic causes), treated between January 2013 and December 2022, comparing SE management, frequency of refractory SE, and clinical outcome, among four patients' groups stratified by SE etiology: Non-neoplastic, Gliomas, Brain metastases, Other brain tumors.

Results: We analyzed 961 episodes in 831 patients (Non-neoplastic: 649, Gliomas: 85, Metastases: 77, Other brain tumors: 20). Although tumor-patients presented more often with focal episodes and less consciousness impairment than non-neoplastic patients, administration of benzodiazepines as first-line treatment (>75% across all groups), and utilization of second-line ASM were similar across groups. Treatment adequacy was marginally higher in glioma patients compared to the non-neoplastic population (p: 0.049), while refractory SE was comparable in all groups (p: 0.269). No significant differences in clinical outcomes were observed (mortality: non-neoplastic (89/649, 13.7%), glioma (8/85, 9.4%), metastases (14/77, 18.2%), other tumors (5/20, 25.0%), p: 0.198; non-neoplastic vs. glioma, p: 0.271) CONCLUSION: Tumor-associated SE represents 1/5 of all SE episodes, and is managed similarly to other SE causes. Treatment responsiveness and short-term clinical outcomes also exhibit comparable results.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.seizure.2024.06.005DOI Listing

Publication Analysis

Top Keywords

brain tumors
12
status epilepticus
8
cohort study
8
treatment flow
8
metastases brain
8
clinical outcomes
8
non-neoplastic
6
patients
5
brain
5
treatment
5

Similar Publications

CDK5: Insights into its roles in diseases.

Mol Biol Rep

January 2025

Institute of Pathogenic Biology, Guilin Medical University, Guilin, 541199, China.

Cyclin-dependent kinase 5 (CDK5), a unique member of the CDK family, is a proline-directed serine/threonine protein kinase with critical roles in various physiological and pathological processes. Widely expressed in the central nervous system, CDK5 is strongly implicated in neurological diseases. Beyond its neurological roles, CDK5 is involved in metabolic disorders, psychiatric conditions, and tumor progression, contributing to processes such as proliferation, migration, immune evasion, genomic stability, and angiogenesis.

View Article and Find Full Text PDF

Brain tumors can cause difficulties in normal brain function and are capable of developing in various regions of the brain. Malignant tumours can develop quickly, pass through neighboring tissues, and extend to further brain regions or the central nervous system. In contrast, healthy tumors typically develop slowly and do not invade surrounding tissues.

View Article and Find Full Text PDF

Mutations in Sonic Hedgehog (SHH) signaling pathway genes, for example, (SUFU), drive granule neuron precursors (GNP) to form medulloblastomas (MB). However, how different molecular lesions in the Shh pathway drive transformation is frequently unclear, and mutations in the cerebellum seem distinct. In this study, we show that fibroblast growth factor 5 (FGF5) signaling is integral for many infantile MB cases and that expression is uniquely upregulated in infantile MB tumors.

View Article and Find Full Text PDF

Introduction: Medulloblastoma (MB) is the most common malignant childhood brain tumor. Molecular subgrouping of MB has become a major determinant of management in high-income countries. Subgrouping is still very limited in low- and middle-income countries (LMICs), and its relevance to management with the incorporation of risk stratification (low risk, standard risk, high risk, and very high risk) has yet to be evaluated in this setting.

View Article and Find Full Text PDF

Utilizing machine-learning techniques on MRI radiomics to identify primary tumors in brain metastases.

Front Neurol

January 2025

Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

Objective: To develop a machine learning-based clinical and/or radiomics model for predicting the primary site of brain metastases using multiparametric magnetic resonance imaging (MRI).

Materials And Methods: A total of 202 patients (87 males, 115 females) with 439 brain metastases were retrospectively included, divided into training sets (brain metastases of lung cancer [BMLC]  = 194, brain metastases of breast cancer [BMBC]  = 108, brain metastases of gastrointestinal tumor [BMGiT]  = 48) and test sets (BMLC  = 50, BMBC  = 27, BMGiT  = 12). A total of 3,404 quantitative image features were obtained through semi-automatic segmentation from MRI images (T1WI, T2WI, FLAIR, and T1-CE).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!